PI4KIII-beta-inhibitor-1

By Targets:	TGF-β Receptor (2) Apoptosis (1) Cholinesterase (ChE) (1) Endogenous Metabolite (1) GSK-3 (2) HCV (3) Parasite (1) PI3K (4) PI4K (12) PKC (1) Reverse Transcriptase (1) Virus Protease (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Infection (7) Inflammation/Immunology (1) Metabolic Disease (2)

Targets Recommended: Amyloid-β TGF-β Receptor Beta-secretase TGF-beta/Smad 17β-HSD β-catenin 11β-HSD Beta-lactamase Dopamine β-hydroxylase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15679

PI4KIII beta inhibitor 3

2 Publications Verification

PI4K Cancer

PI4KIII beta inhibitor 3 is a novel and high effective PI4KIIIβ inhibitor with IC₅₀ of 5.7 nM.

PI4KIII beta inhibitor 3 2 Publications Verification	PI4K	Cancer
PI4KIII beta inhibitor 3 is a novel and high effective PI4KIIIβ inhibitor with IC₅₀ of 5.7 nM.

HY-18748

BQR-695 1 Publications Verification NVP-BQR695	PI4K Parasite	Infection
BQR-695 is a PI4KIIIβ inhibitor with IC₅₀s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.

HY-106012

PI4K-IN-1	PI4K PI3K	Cancer
PI4K-IN-1 (compound 44) is a potent *PI4KIII* inhibitor, with pIC₅₀ values of 9.0 and 6.6 for PI4KIIIα and PI4KIIIβ, respectively. PI4K-IN-1 also inhibits PI3Kα/β/γ/δ, with pIC₅₀ values of 4.0/<3.7/5.0/<4.1, respectively ^[1].

HY-110248

MI 14	PI4K HCV	Infection
MI 14 is a selective PI4KIIIβ inhibitor with IC₅₀s of 54 nM, >100 μM, >100 μM for PI4KIIIβ, PI4KIIIα, PI4KIIα, respectively. MI 14 has antiviral activity against HCV 1b, CVB3, HRVM, HVC 2a ^[1].

HY-148075

PI4KIIIbeta-IN-11	PI4K	Infection
PI4KIIIbeta-IN-11 is an inhibitor of PI4KIIIβ, with a mean pIC₅₀ value of at least 9.1. PI4KIIIβ plays a key role in diseases research of RNA viruses and Plasmodium falciparum ^[1] .

HY-U00426

BF738735

2 Publications Verification

PI4K Reverse Transcriptase Infection

BF738735 is a phosphatidylinositol 4-kinase III beta (PI4KIIIβ) inhibitor with an IC₅₀ of 5.7 nM.
HY-118525

AL-9

HCV PI4K Infection

AL-9 is a inhibitor of PI4KIIIα, with the IC₅₀ of 0.57 μM, that can inhibit HCV replication ^[1].
HY-100198

PI4KIIIbeta-IN-10

Maximum Cited Publications

13 Publications Verification

PI4K PI3K Infection

PI4KIIIbeta-IN-10 is a potent PI4KIIIβ inhibitor with an IC₅₀ of 3.6 nM.

BF738735 2 Publications Verification	PI4K Reverse Transcriptase	Infection
BF738735 is a phosphatidylinositol 4-kinase III beta (PI4KIIIβ) inhibitor with an IC₅₀ of 5.7 nM.

AL-9	HCV PI4K	Infection
AL-9 is a inhibitor of PI4KIIIα, with the IC₅₀ of 0.57 μM, that can inhibit HCV replication ^[1].

PI4KIIIbeta-IN-10 Maximum Cited Publications 13 Publications Verification	PI4K PI3K	Infection
PI4KIIIbeta-IN-10 is a potent PI4KIIIβ inhibitor with an IC₅₀ of 3.6 nM.

HY-12046

PIK-93 4 Publications Verification	PI4K PI3K Virus Protease	Cancer
PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC₅₀ of 19 nM, and also inhibits PI3Kγ and PI3Kα with IC₅₀ of 16 nM and 39 nM, respectively.

HY-112613

UCB9608 1 Publications Verification	PI4K	Inflammation/Immunology
UCB9608 is a potent, selective and orally active PI4KIIIβ inhibitor, with an IC₅₀ of 11 nM, selective over PI3KC2 α, β, and γ lipid kinases. UCB9608 improves metabolic stability and exhibits excellent pharmacokinetic profile, acts as a potent immunosuppressive agent ^[1].

HY-19798

PI4KIIIbeta-IN-9 5 Publications Verification	PI4K PI3K	Cancer
PI4KIIIbeta-IN-9 is a potent PI4KIIIβ inhibitor with an IC₅₀ of 7 nM. PI4KIIIbeta-IN-9 also inhibits PI3Kδ and PI3Kγ with IC₅₀s of 152 nM and 1046 nM, respectively.

HY-125118

GSK-A1	PI4K HCV	Infection
GSK-A1 is a selective *type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα)* inhibitor with a pIC₅₀ of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC₅₀ of about 3 nM. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2. GSK-A1 has the potential for anti-hepatitis C virus (HCV) research ^[1].

HY-126144A

(E/Z)-GSK-3β inhibitor 1	GSK-3	Metabolic Disease
(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC₅₀ of 4.9 nM ^[1].

HY-126144

GSK-3β inhibitor 1 2 Publications Verification	GSK-3	Metabolic Disease
GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC₅₀ of 4.9 nM ^[1].

HY-P5189A

*His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA*	Endogenous Metabolite Cholinesterase (ChE)	Others
His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA, is a growth hormone releasing peptide, as well as a metabolite of GHRP-1. GHRP-1, or Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2, has the effect of promoting the release of growth hormone (GH). GHRP-1 increases GH release and increases [Ca2+]i levels in static monolayer cells of rat pituitary gland, but does not affect cAMP levels ^[1].

HY-118810

BIO-013077-01

TGF-β Receptor Cancer

BIO-013077-01 is a pyrazole TGF-β inhibitor ^[1].

BIO-013077-01	TGF-β Receptor	Cancer
BIO-013077-01 is a pyrazole *TGF-β* inhibitor ^[1].

HY-123900

AZ12799734	TGF-β Receptor	Cardiovascular Disease
AZ12799734 is a selective, orally active *TGFBR1* kinase inhibitor with an IC₅₀ of 47 nM. AZ12799734 is also a pan BMP and TGFβ inhibitor ^[1].

HY-13335

*PKCβ inhibitor* 1**	PKC Apoptosis	Cancer
PKCβ inhibitor 1 is a potent, ATP-competitive, and selective PKCβ inhibitor with IC₅₀s of 21 and 5 nM for human PKCβ1 and PKCβ2, respectively. PKCβ inhibitor 1 exhibits selectivity of more than 60-fold in favor of PKCβ2 relative to other PKC isozymes (PKCα, PKCγ, and PKCε) ^[1] .

HY-101019

Ossirene 1 Publications Verification AS101
Ossirene (AS101), an immunomodulatory tellurium compound, is a potent *IL-1β* inhibitor ^[1]. Ossirene abolishes phosphorylation of STAT3 by inhibiting IL-10. Ossirene potently inhibits *Caspase-1* and is used for the autoimmune diseases and certain malignancies ^[4].

Cat. No.	Product Name	Target	Research Area

HY-P4285

β-Aspartylalanine

Peptides Others

β-Aspartylalanine is a substrate for β-aspartyl peptidase and used to measure β-aspartyl peptidase activity in fecal supernatants ^[1].

β-Aspartylalanine	Peptides	Others
β-Aspartylalanine is a substrate for β-aspartyl peptidase and used to measure β-aspartyl peptidase activity in fecal supernatants ^[1].

HY-P5189A

*His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA*	Endogenous Metabolite Cholinesterase (ChE)	Others
His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA, is a growth hormone releasing peptide, as well as a metabolite of GHRP-1. GHRP-1, or Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2, has the effect of promoting the release of growth hormone (GH). GHRP-1 increases GH release and increases [Ca2+]i levels in static monolayer cells of rat pituitary gland, but does not affect cAMP levels ^[1].

Cat. No.	Compare	Product Name	Species	Source

HY-P701742

	PI4KB Protein, Human (Sf9, His, GST) PI4KB; Phosphatidylinositol 4-kinase beta; PI4K-beta; PI4Kbeta; PtdIns 4-kinase beta; NPIK; PI4K92; PI4KIII	Human	Sf9 insect cells
	The PI4KB protein is a key enzyme that initiates the production of 1,4,5-trisphosphate inositol (PIP) by phosphorylating phosphatidylinositol (PI). In addition to myo-inositol signaling, it is involved in mitotic Golgi disassembly and Golgi-to-plasma membrane trafficking, which is critical for cell membrane dynamics. PI4KB Protein, Human (Sf9, His, GST) is the recombinant human-derived PI4KB protein, expressed by Sf9 insect cells , with N-8*His, N-GST labeled tag. The total length of PI4KB Protein, Human (Sf9, His, GST) is 815 a.a., .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Recombinant Proteins

Name
Email *

	Sorry, but the email address you supplied was invalid.